(2-(N-(tert-butyl)sulfamoyl)-5-isobutylphenyl)boronic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-(N-(tert-butyl)sulfamoyl)-5-isobutylphenyl)boronic acid
• 英文别名: [2-(Tert-butylsulfamoyl)-5-(2-methylpropyl)phenyl]boronic acid
• 化学式: C₁₄H₂₄BNO₄S
• 分子量: 313.226
• InChiKey: JEZABJIWXOWEGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.64
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-(N-(tert-butyl)sulfamoyl)-5-isobutylphenyl)boronic acid 在 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 5.0h， 生成 butyl ((4'-((2-(tert-butyl)-1H-imidazol-1-yl)methyl)-3'-fluoro-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
  参考文献：
  名称：

  [EN] SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS
  [FR] LIGANDS SÉLECTIFS DU RÉCEPTEUR DE L'ANGIOTENSINE II

  摘要：

  提供了式子I的药物化合物，其中R1、R2、R3、R4、R6、X、Y、Z、Y1、Y2、Y3和Y4的含义在说明中给出，这些化合物在治疗自身免疫和/或纤维化疾病方面有用，包括间质性肺病，如特发性肺纤维化和结节病。

  公开号：

  WO2022200785A1
• 作为产物：
  描述：

  异丁基苯 在 氯磺酸 、 正丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯仿 为溶剂， 反应 12.75h， 生成 (2-(N-(tert-butyl)sulfamoyl)-5-isobutylphenyl)boronic acid
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates

  摘要：

  A series of novel 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives were designed and synthesized to develop new angiotensin II subtype 2 (AT(2)) receptor agonists as novel antihypertensive candidates. It was found that 14f (IC50 = 0.4 nM) and 15e (IC50 = 5.0 nM) displayed potent AT(2) receptor affinity and selectivity in binding assays. Biological evaluation in vivo suggested that 14f is obviously superior to that of reference drug losartan in RHRs, and meanwhile, 14f has no significant impact on heart rate. The interesting activities of these compounds may make them promising candidates as antihypertensive agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.017

文献信息

• Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT₂ Receptor Ligands
  作者：Charlotta Wallinder、Christian Sköld、Milad Botros、Marie-Odile Guimond、Mathias Hallberg、Nicole Gallo-Payet、Anders Karlén、Mathias Alterman

  DOI：10.1021/ml500427r

  日期：2015.2.12

  Migration of the methylene imidazole side chain in the first reported selective drug-like AT2 receptor agonist C21/M024 (1) delivered the AT2 receptor antagonist C38/M132 (2). We now report that the AT2 receptor antagonist compound 4, a biphenyl derivative that is structurally related to 2, is transformed to the agonist 6 by migration of the isobutyl group. The importance of the relative position of

  亚甲基咪唑侧链在第一个报道的选择性药物样AT 2受体激动剂C21 / M024（1）中的迁移提供了AT 2受体拮抗剂C38 / M132（2）。现在我们报告AT 2受体拮抗剂化合物4，一种与2结构相关的联苯衍生物，通过异丁基的迁移转化为激动剂6。本文突出了亚甲基咪唑和异丁基取代基的相对位置的重要性。
• 作为AT2R激动剂的杂环化合物
  申请人：武汉人福创新药物研发中心有限公司

  公开号：CN116891463A

  公开（公告）日：2023-10-17

  本发明提供了式I所示杂环化合物、其互变异构体、立体异构体、水合物、溶剂化物、药学上可接受的盐或前药；所述杂环化合物对与AT2受体相关疾病有治疗作用，#imgabs0#
• Selective Angiotensin II AT₂ Receptor Agonists:  Arylbenzylimidazole Structure−Activity Relationships
  作者：Xiongyu Wu、Yiqian Wan、A. K. Mahalingam、A. M. S. Murugaiah,、Bianca Plouffe、Milad Botros、Anders Karlén、Mathias Hallberg、Nicole Gallo-Payet、Mathias Alterman

  DOI：10.1021/jm0606185

  日期：2006.11.30

  Structural alterations in the 2- and 5-positions of the first drug-like selective angiotensin II AT(2) receptor agonist (1) have been performed. The imidazole ring system was proven to be a strong determinant for the AT(2) selectivity, and with few exceptions all variations gave good AT(2) receptor affinities and with retained high AT(2)/AT(1) selectivities. On the contrary to the findings with AT(1) receptor agonists, the impact of structural modifications in the 5-position of the AT(2) selective compounds were less pronounced regarding activation of the AT(2) receptor. The butyloxyphenyl (56) and the propylthienyl (50) derivatives were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.
• Selective angiotensin II AT2 receptor agonists: Benzamide structure–activity relationships
  作者：Charlotta Wallinder、Milad Botros、Ulrika Rosenström、Marie-Odile Guimond、Hélène Beaudry、Fred Nyberg、Nicole Gallo-Payet、Anders Hallberg、Mathias Alterman

  DOI：10.1016/j.bmc.2008.05.066

  日期：2008.7

  In the investigation of the structure-activity relationship of nonpeptide AT(2) receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT(2) receptor agonist M024 have been synthesised. In a second series, the biphenyl scaffold was compared to the thienylphenyl scaffold and the impact of the isobutyl substituent and its position on AT(1)/AT(2) receptor selectivity was also investigated. Both series included several compounds with high af. nity and selectivity for the AT(2) receptor. Three of the compounds were also proven to function as agonists at the AT(2) receptor, as deduced from a neurite outgrowth assay, conducted in NG108-15 cells. (c) 2008 Elsevier Ltd. All rights reserved.
• SELECTIVE ANGIOTENSIN II COMPOUNDS
  申请人：[en]VICORE PHARMA AB

  公开号：WO2024149712A1

  公开（公告）日：2024-07-18

  There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.